The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab

BACKGROUND: Immunotherapy targeting programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) has become the forefront strategy for systemic therapy in advanced non-small cell lung cancer (NSCLC) patients. PD-L1 expression on tumor cells has been reported as an eligible biomarker of respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsubara, Taichi, Takamori, Shinkichi, Haratake, Naoki, Toyozawa, Ryo, Miura, Naoko, Shimokawa, Mototsugu, Yamaguchi, Masafumi, Seto, Takashi, Takenoyama, Mitsuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212122/
https://www.ncbi.nlm.nih.gov/pubmed/32395289
http://dx.doi.org/10.21037/jtd.2020.02.27

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212122/
https://www.ncbi.nlm.nih.gov/pubmed/32395289
http://dx.doi.org/10.21037/jtd.2020.02.27

Ejemplares similares